Doximity (DOCS) Stock Forecast & Price Target

Doximity is benefiting from a strong core business, with Q1 revenue of $157M, up 7% year over year, and adjusted EBITDA of $75M at a 48% margin, while net revenue retention remained healthy at 107% and the company held $688M in cash with no debt as of June 30. Its outlook is further strengthened by AI Search and AI Scribe, where more than two dozen pharma programs are live, usage is up 10x year over year, and management said AI Search can generate more than 10x revenue relative to cost, signaling attractive monetization potential. The bullish case is supported by rising physician engagement, a growing AI commercial pipeline, and a favorable litigation outcome or faster-than-guided monetization that could reduce the competitive discount embedded in the stock.

Doximity is fundamentally challenged by its heavy reliance on pharma-funded marketing, with over 90% of revenue tied to short-cycle contracts and a market that management says is growing at or below 5%, far below its historical pace. Late in CY25, MFN pricing agreements caused major clients to delay budget commitments, while competition from AI-native apps, OpenEvidence, and Epic Systems limits the chance that AI search will offset slower core demand. Further, cybersecurity, PHI-related data restrictions, and weaker confidence in FY27 growth cadence and adjusted EBITDA reflect a business with limited visibility and rising execution risk.